Investing.comDoubao · 实盘不做把握 6/10不做原因:已被定价
北京时间·🕒 发布 19:04:35·⟳ 抓取 19:05:11 +36s·⚡ 决策 10-12 19:07:14 +2m03s·14.8 天前
百时美施贵宝（Bristol Myers Squibb）RYZ101 三期 ACTION-1 中期分析达到主要终点 PFS，GEP-NET 罕见瘤种
事件方向确为正面且有公司官方新闻稿，但 RYZ101 针对美国年新发约 1.8 万例的罕见瘤种、尚未申报上市，峰值销售对 $1200 亿市值、年收入数百亿美元的 BMY 占比很小；消息 7:04 ET 发布后盘前已冲高至 +4.9%（区间 57.32–63.56，双向剧烈），核心反应在可成交前已大体定价，topline 又缺 HR/OS 等关键数据，追高 edge 与风险收益不佳。
📄 原文Investing.com↗ 原文
Bristol Myers Squibb’s RYZ101 meets primary endpoint in trial
By Investing.com Advertisement Advertisement Bristol Myers Squibb’s RYZ101 meets primary endpoint in trial Company News…
不做 Bristol Myers Squibb（BMY.US）
罕见瘤种三期阳性对超大市值公司业绩弹性小，盘前已冲高 +4.9%（区间宽、双向震荡）核心利好开盘前大体 price-in，且 topline 缺 HR/OS；追高风险收益不足，事件为正面故不做空，等完整数据或回踩承接再评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
BMY 的锕-225 放射性药物 RYZ101 三期达到 PFS 主要终点，是平台性验证的真实利好；但罕见瘤种对超大市值公司业绩弹性有限，盘前已涨约 5% 且剧烈震荡，缺乏剩余 edge，不做多也不做空。
消息传播链
- BMS 官宣 ACTION-1 中期分析 PFS 阳性，为本次催化首发；Investing.com 07:04 ET 同步报道市场反应:BMY 盘前由参考价 59.12 升至约 62.0（+4.9%），区间 57.32–63.56，量约 11.8 万股
关键理由
- 首个 α 同位素靶向放射性药物三期阳性具有平台验证意义，并为 GEP-NET 后线治疗打开申报路径
- 相对 BMY 约 $1200 亿市值与现有收入基数，该孤儿药近期收入弹性小，难支撑持续大幅重定价
主要风险
- topline 未披露 HR/置信区间，完整数据若临床意义有限或 OS 不改善可能反转
- 盘前区间宽（57.32–63.56）且已 +4.9%，常规时段易高开回落，追高承担跳空回撤风险
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-12 · 影响 weakens
topline 仅称 PFS 统计学显著，未给 HR/CI，OS 仍在随访，尚未申报；监管路径与临床意义幅度存在不确定性
检索:RYZ101 ACTION-1 HR overall survival safety concerns FDA additional trial 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-10-12 · 影响 weakens
美国 GEP-NET 年新发约 1.8 万例且为后线亚群，对应峰值销售相对 BMY 约 $1200 亿市值弹性有限
检索:BMY market cap RYZ101 peak sales GEP-NET patient population radiopharmaceutical 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例薄弱叠加盘前已大幅跳空，支持不追高（AVOID）而非设定入场/止盈止损。
方向:未在本轮取得可溯源首发、同市场同相位的大市值药企罕见瘤种三期 topline 先例面板，不据记忆编造涨幅。
涨幅量级:缺乏高相似对齐先例，无法用先例校准 tp/sl；仅有盘前实际 +4.9% 的市场即时定价作参考。
形态:不足以判断见光死概率，但盘前宽幅震荡提示双向分歧。
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`bmy rayzebio actinium-225 dotatate phase 3 pfs neuroendocrine tumors | bristol myers squibb ryz101 action-1 primary endpoint gep-net`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 成功 stock_tools HTTP · 631 ms
{ - web_search 成功 doubao_search · 2,813 ms
豆包搜索结果（原始查询:Bristol Myers Squibb RYZ101 ACTION-1 trial primary endpoint RayzeBio press release；API SearchType:web）
原文全文
展开原文 · 7,483 字
Bristol Myers Squibb’s RYZ101 meets primary endpoint in trial By Investing.com
Advertisement
Advertisement
Bristol Myers Squibb’s RYZ101 meets primary endpoint in trial
Company News
Published
Oct 12, 2026, 07:04 AM
Bristol Myers Squibb’s RYZ101 meets primary endpoint in trial
View all comments (0)
0
Bristol Myers Squibb’s RYZ101 meets primary endpoint in trial
View all comments (0)
0
© Reuters
In this article:
BMY
-0.77%
PRINCETON, N.J. - Bristol Myers Squibb (
NYSE:BMY
) announced today that its ACTION-1 trial met its primary endpoint, showing a statistically significant improvement in progression-free survival for patients with gastroenteropancreatic neuroendocrine tumors, according to a press release statement.
The Phase 3 trial evaluated RYZ101, an investigational radiopharmaceutical therapy, versus standard of care treatments in patients with somatostatin receptor-positive GEP-NETs who progressed following Lutetium-177 based therapy. The planned interim analysis showed the treatment improved progression-free survival by blinded independent central review, with safety results consistent with the known RYZ101 safety profile.
RYZ101 is comprised of DOTATATE bound to Actinium-225, an alpha-emitting radioisotope. The company stated these are the first results from a Phase 3 trial of an alpha-isotope based targeted radiopharmaceutical therapy in any indication.
"This is the kind of impact we set out to deliver with actinium-based radiopharmaceuticals," said Amreen Husain, chief medical officer of RayzeBio, a Bristol Myers Squibb company.
The FDA granted RYZ101 Orphan Drug Designation for the treatment of GEP-NETs in August 2026. Bristol Myers Squibb plans to engage with the FDA to discuss next steps toward a regulatory submission. Detailed results are expected to be presented at a future medical meeting.
GEP-NETs are rare tumors with an estimated incidence of approximately 18,000 patients diagnosed annually in the United States. The company stated that most patients progress following Lu177-based therapy, with few effective treatment options available.
Participants currently enrolled will continue to receive care consistent with the study protocol and will be followed for overall survival.
RYZ101 is also being evaluated in earlier-stage trials in hormone receptor-positive metastatic breast cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Bristol Myers Squibb’s RYZ101 meets primary endpoint in trial
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,694.60
+39.4
+0.08%
US 500
7,813.70
+2.2
+0.03%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.50
+0.66
+4.45%
Dollar Index
102.21
+0.188
+0.18%
Crude Oil WTI Futures
92.92
+1.07
+1.16%
Brent Oil Futures
105.97
+1.25
+1.19%
Natural Gas Futures
3.145
-0.075
-2.33%
Gold Futures
4,199.30
-17.00
-0.40%
Silver Futures
60.90
-0.148
-0.24%
Copper Futures
6.7668
+0.0748
+1.12%
US Soybeans Futures
1,282.88
-8.13
-0.63%
U.S. 10Y
5.256
+0.012
+0.23%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.53
-0.06
-0.06%
Euro Bund Futures
121.05
-0.03
-0.03%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
What the sell off in bonds means for monetary policy
By Investing.co
...
Oct 11, 2026
Broadcom CEO says many AI investors are gamblers
By Investing.co
...
Oct 12, 2026
Premarket movers: Iren jumps on Anthropic deal, CCC surges on buyout talks
By Investing.co
...
Oct 12, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Bristol Myers Squibb’s RYZ101 meets primary endpoint in trial
Company News
Published
Oct 12, 2026, 07:04 AM
Bristol Myers Squibb’s RYZ101 meets primary endpoint in trial
View all comments (0)
0
Bristol Myers Squibb’s RYZ101 meets primary endpoint in trial
View all comments (0)
0
© Reuters
In this article:
BMY
-0.77%
PRINCETON, N.J. - Bristol Myers Squibb (
NYSE:BMY
) announced today that its ACTION-1 trial met its primary endpoint, showing a statistically significant improvement in progression-free survival for patients with gastroenteropancreatic neuroendocrine tumors, according to a press release statement.
The Phase 3 trial evaluated RYZ101, an investigational radiopharmaceutical therapy, versus standard of care treatments in patients with somatostatin receptor-positive GEP-NETs who progressed following Lutetium-177 based therapy. The planned interim analysis showed the treatment improved progression-free survival by blinded independent central review, with safety results consistent with the known RYZ101 safety profile.
RYZ101 is comprised of DOTATATE bound to Actinium-225, an alpha-emitting radioisotope. The company stated these are the first results from a Phase 3 trial of an alpha-isotope based targeted radiopharmaceutical therapy in any indication.
"This is the kind of impact we set out to deliver with actinium-based radiopharmaceuticals," said Amreen Husain, chief medical officer of RayzeBio, a Bristol Myers Squibb company.
The FDA granted RYZ101 Orphan Drug Designation for the treatment of GEP-NETs in August 2026. Bristol Myers Squibb plans to engage with the FDA to discuss next steps toward a regulatory submission. Detailed results are expected to be presented at a future medical meeting.
GEP-NETs are rare tumors with an estimated incidence of approximately 18,000 patients diagnosed annually in the United States. The company stated that most patients progress following Lu177-based therapy, with few effective treatment options available.
Participants currently enrolled will continue to receive care consistent with the study protocol and will be followed for overall survival.
RYZ101 is also being evaluated in earlier-stage trials in hormone receptor-positive metastatic breast cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Bristol Myers Squibb’s RYZ101 meets primary endpoint in trial
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,694.60
+39.4
+0.08%
US 500
7,813.70
+2.2
+0.03%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.50
+0.66
+4.45%
Dollar Index
102.21
+0.188
+0.18%
Crude Oil WTI Futures
92.92
+1.07
+1.16%
Brent Oil Futures
105.97
+1.25
+1.19%
Natural Gas Futures
3.145
-0.075
-2.33%
Gold Futures
4,199.30
-17.00
-0.40%
Silver Futures
60.90
-0.148
-0.24%
Copper Futures
6.7668
+0.0748
+1.12%
US Soybeans Futures
1,282.88
-8.13
-0.63%
U.S. 10Y
5.256
+0.012
+0.23%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.53
-0.06
-0.06%
Euro Bund Futures
121.05
-0.03
-0.03%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
What the sell off in bonds means for monetary policy
By Investing.co
...
Oct 11, 2026
Broadcom CEO says many AI investors are gamblers
By Investing.co
...
Oct 12, 2026
Premarket movers: Iren jumps on Anthropic deal, CCC surges on buyout talks
By Investing.co
...
Oct 12, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
3391e7f474· 2026-10-12 19:07 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前